AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24144643
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of elevated serum free light chain, M-spike, and GEP70 risk score
Trial: 24145340
Drug: Dose-escalated hypofractionated
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-escalated hypofractionated radiotherapy (RT) with total doses ranging from 57 to 85.5 Gy in 25 daily fractions over 5 weeks using intensity-modulated radiotherapy.
Trial: 24145340
Drug: Dose-escalated hypofractionated
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-escalated hypofractionated radiotherapy (RT)
Trial: 24145345
Drug: Nivolumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab with vaccine
Trial: 24145345
Drug: Nivolumab at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab at 3 mg/kg with or without peptide vaccine
Trial: 24145880
Drug: Ritonavir-boosted atazanavir
RxNorm normalized name: atazanavir and ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir-boosted atazanavir (ATVr) 300/100 mg every 24 hours
Trial: 24145880
Drug: Unboosted atazanavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unboosted atazanavir (200 mg every 12 hours)
Trial: 24145879
Drug: Raltegravir as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir as a film-coated tablet 400 mg twice daily (6 to <19 years, and ≥ 25 kg)
Trial: 24145879
Drug: Raltegravir as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir as a chewable tablet 6 mg/kg (maximum dose 300 mg) twice daily (2 to <12 years)
Trial: 24145879
Drug: Raltegravir (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir (both formulations)
Trial: 24146220
Drug: Panitumumab (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panitumumab (9 mg/kg) + Gemcitabine (1000 mg/m(2)) + Irinotecan (100 mg/m(2))
Trial: 24148552
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate (TDF) 300 mg once daily (single dose on day 1 and multiple doses on days 4-10)
Trial: 24151550
Drug: Plant stanol
RxNorm normalized name: plant stanol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant stanol ester (STAEST) in soymilk-based minidrink (2.7 g/d, 65 mL/d)
Trial: 24152880
Drug: Specialised palliative
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialised palliative care (SPC) plus standard treatment
Trial: 24153347
Drug: Cyclooxygenase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclooxygenase inhibitors (NSAIDs) >6 months
Trial: 24155157
Drug: Tigecycline (100-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tigecycline (100-mg infusion followed by two 50-mg infusions, each administered over 30 minutes)
Trial: 24156629
Drug: Community health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community health coach integration, home blood pressure monitoring, standardized care delivery processes, and improved medication adherence
Trial: 24157897
Drug: Paracetamol-Morphine Combination
RxNorm normalized name: morphine, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol-Morphine Combination
Trial: 24157897
Drug: Paracetamol and
RxNorm normalized name: Paracetamol and tramadol only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol and Morphine Combination
Trial: 24158411
Drug: Trastuzumab, lapatinib,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab, lapatinib, and bevacizumab (trastuzumab 8 mg/kg loading dose, 6 mg/kg maintenance dose, intravenously every 3 weeks; lapatinib 1250 mg daily; bevacizumab 15 mg/kg intravenously every 3 weeks)
Trial: 24159060
Drug: tPA alone
RxNorm normalized name: tPA
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tPA alone (standard-dose intravenous)
Trial: 24161160
Drug: Rilpivirine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilpivirine (25 mg once daily) co-administered with ethinylestradiol (35 μg)/norethindrone (1 mg)
Trial: 24161161
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous dose of tocilizumab (TCZ)
Trial: 24161161
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (OC; norethindrone (NE) and ethinyl estradiol (EE))
Trial: 24161161
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (OC) with or without a single dose of TCZ
Trial: 24165173
Drug: Anidulafungin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anidulafungin (100 mg once daily after a loading dose of 200 mg on the first day)
Trial: 24166890
Drug: Continued medical
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued medical therapy (CMT) for a mean of 7.1 months
Trial: 24168522
Drug: EEG-neurofeedback treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EEG-neurofeedback treatment
Trial: 24168522
Drug: Placebo-neurofeedback treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-neurofeedback treatment
Trial: 24170610
Drug: GDC-0449 150
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GDC-0449 150 mg/day (days 1-28, 28-day cycle)
Trial: 24171147
Drug: Naltrexone 32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone 32 mg/d and Bupropion 360 mg/d (NB32) with dietary and behavioral counseling
Trial: 24171941
Drug: Combined positive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined positive imagery CBM and internet cognitive behavioural therapy (iCBT)
Trial: 24172304
Drug: Baseline characteristics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline characteristics (plasma insulin, IL-6, adipose tissue inflammation, Lactobacillus/Leuconostoc/Pediococcus numbers)
Trial: 24173967
Drug: Dasatinib (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib (70 mg daily) in combination with capecitabine (850 mg/m² twice daily, days 1-14), oxaliplatin (130 mg/m² on day 1), and bevacizumab (7.5 mg/kg on day 1), every 3 weeks
Trial: 24173967
Drug: Dasatinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib (50 mg bid)
Trial: 24173967
Drug: Dasatinib (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib (70 mg daily)
Trial: 24177180
Drug: Anti-OX40 monoclonal
RxNorm normalized name: Agonistic anti-OX40 monoclonal antibody MEDI6469
DrugBank: MEDI-6469 (DB15306)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-OX40 monoclonal antibody (mAb)
Trial: 24177377
Drug: Fluticasone therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone therapy
Trial: 24184736
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) 400 mg subcutaneously at weeks 0, 2, and 4, then every 4 weeks until week 52
Trial: 24188875
Drug: 25 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 μg recombinant hCG (r-hCG)
Trial: 24193798
Drug: RP-1127 (glyburide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RP-1127 (glyburide for injection) at a dose of 3 mg/d
Trial: 24195547
Drug: Biopsies with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biopsies with antibody-mediated rejection or acute tubular necrosis
Trial: 24196401
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment during pregnancy
Trial: 24200517
Drug: Automated text
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated text message based weight loss program (3-5 text messages daily for 8 weeks, including printed materials and weekly counseling calls)
Trial: 24201857
Drug: Single-dose IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose IV sildenafil (0.25, 0.35, or 0.45 mg/kg over 20 min)
Trial: 24211066
Drug: Intramyocardial injection
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramyocardial injection of autologous bone-marrow derived mesenchymal stromal cells (BMMSCs)
Trial: 24214905
Drug: Cefazolin 2
RxNorm normalized name: cefazolin 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin 2 g intravenously before surgery
Trial: 24218035
Drug: Sorafenib (So)
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib (So) treatment
Trial: 24218513
Drug: Imiquimod ointment
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imiquimod ointment and subcutaneous vaccinations (100 μg IDO5 peptide, sequence ALLEIASCL, formulated in 900 μL Montanide)
Trial: 24220277
Drug: CBT intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CBT intervention with weekly therapist contact
Trial: 24220703
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg mifepristone vaginally daily for 3 months
Trial: 24221839
Drug: CVD-medication nonadherence
RxNorm normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVD-medication nonadherence
Trial: 24223036
Drug: Integrated cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated cognitive behavioral therapy
Trial: 24224560
Drug: Recombinant viruslike
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant viruslike particle influenza A (H7N9) vaccine
Trial: 24225051
Drug: 4-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-day course of corticosteroid treatment
Trial: 24225051
Drug: No corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No corticosteroid treatment
Trial: 24228627
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of short cervix and IL-8
Trial: 24229439
Drug: Subcutaneous-allergen-specific-immunotherapy (SCIT)
RxNorm normalized name: Pacific halibut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous-allergen-specific-immunotherapy (SCIT)
Trial: 24232700
Drug: Intrabronchial valve
RxNorm normalized name: VALVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrabronchial valve treatment
Trial: 24234516
Drug: p53 antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p53 antibody testing in patients with thyroid cancer
Trial: 24234516
Drug: p53 antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p53 antibody testing in healthy subjects
Trial: 24234516
Drug: p53 antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p53 antibody testing in dedifferentiated patients with high Tg level and negative radioiodine scan
Trial: 24241210
Drug: Flavopiridol (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavopiridol (30 mg/m² bolus, 30 mg/m² continuous infusion to 50 mg/m² bolus, and 50 mg/m² continuous infusion)
Trial: 24242861
Drug: AS1411 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS1411 (40 mg/kg/day by continuous intravenous infusion on days 1-4 of a 28-day cycle, for two cycles)
Trial: 24246506
Drug: Low-dose paclitaxel
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose paclitaxel (15 mg/m² IV) with timed thoracic radiotherapy (TTR) (total 55 Gy) followed by adjuvant chemotherapy (carboplatin AUC 5 on day 1, gemcitabine 1000 mg/m² on days 1 and 8, every 21 days for 4 cycles)
Trial: 24246506
Drug: Low-dose paclitaxel
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose paclitaxel with concurrent TTR
Trial: 24246704
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg orally per day, with dose escalation by 25mg every two weeks until grade 2/tolerable rash or other dose limiting toxicity developed.
Trial: 24246704
Drug: Erlotinib dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib dose escalation to the development of grade 2 skin rash.
Trial: 24246704
Drug: Comparison to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison to first-line chemotherapy.
Trial: 24246789
Drug: Caregiver Pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caregiver Pain Medicine Questionnaire
Trial: 24247327
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D insufficiency (<75 nmol/L)
Trial: 24251951
Drug: Insulin-resistant group
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-resistant group (HOMA-IR >4)
Trial: 24251951
Drug: Insulin-sensitive group
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-sensitive group (HOMA-IR ≤ 4)
Trial: 24252402
Drug: MK-2206 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-2206 (60 mg QOD schedule)
Trial: 24252402
Drug: MK-2206 (135
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-2206 (135 mg QW schedule)
Trial: 24252402
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MK-2206 and trastuzumab
Trial: 24253138
Drug: Extended heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended heparin prophylaxis (4 weeks)
Trial: 24253138
Drug: Short heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short heparin prophylaxis (1 week)
Trial: 24254708
Drug: Drug-eluting absorbable
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting absorbable metal scaffold
Trial: 24255769
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/kg) and carboplatin (AUC 5.5) administered for 3 cycles after resection for curative intent.
Trial: 24256329
Drug: Low-dose rate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rate brachytherapy
Trial: 24257514
Drug: Raw vegetable
RxNorm normalized name: raw vegetable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raw vegetable intake (68 g per 1000 kcal)
Trial: 24257514
Drug: Cooked vegetable
RxNorm normalized name: egg shell, cooked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooked vegetable intake (92 g per 1000 kcal)
Trial: 24258465
Drug: E7107 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7107 at 5.7 mg/m(2)
Trial: 24258465
Drug: E7107 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7107 at 4.3 mg/m(2)
Trial: 24258465
Drug: E7107 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7107 (various doses)
Trial: 24258465
Drug: E7107 (3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7107 (3.2 mg/m(2) and 4.3 mg/m(2))
Trial: 24261605
Drug: Acetylcholinesterase inhibitors
RxNorm normalized name: acetylcholinesterase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcholinesterase inhibitors (CEIs)
Trial: 24261605
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no anti-dementia drugs)
Trial: 24261996
Drug: BPZE1 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPZE1 administered intranasally before RSV infection
Trial: 24261996
Drug: BPZE1 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPZE1 administered neonatally
Trial: 24261996
Drug: Anti-IL-17 antibodies
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-IL-17 antibodies
Trial: 24262016
Drug: Opioid administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Opioid administration specifically for the procedure
Trial: 24263064
Drug: gefitinib 250
RxNorm normalized name: gefitinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gefitinib 250 mg day(-1) until progression
Trial: 24263462
Drug: Velaglucerase alfa
RxNorm normalized name: Velaglucerase alfa
DrugBank: Velaglucerase alfa (DB06720)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Velaglucerase alfa (60 U/kg for treatment-naïve patients; 15-60 U/kg for previously treated patients)
Trial: 24264034
Drug: Topical ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ketorolac 0.45%, 4 times daily, for 3 days before surgery
Trial: 24264034
Drug: Topical ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ketorolac 0.45%
Trial: 24265670
Drug: Rapamycin (preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapamycin (preventive treatment for 25 days starting one day before myosin immunization)
Trial: 24265670
Drug: Rapamycin (curative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapamycin (curative treatment for 10 days following the last myosin immunization)
Trial: 24267310
Drug: Novel medical
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel medical therapies for pulmonary arterial hypertension
Trial: 24267809
Drug: Bupropion therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion therapy
Trial: 24270505
Drug: β blockers
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β blockers started during hospital admission for myocardial infarction
Trial: 24270505
Drug: Patients already
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients already taking β blockers before myocardial infarction
Trial: 24270505
Drug: β blockers
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β blockers started during hospital admission for myocardial infarction (follow-up from discharge)
Trial: 24273046
Drug: chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy alone (HER2-negative disease)
Trial: 24273135
Drug: Liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal doxorubicin (40 mg/m² on day 1), vincristine (2 mg on day 1), dexamethasone (40 mg on days 1-4), lenalidomide (10 mg on days 1-21 of every 28-day cycle) followed by lenalidomide maintenance therapy.
Trial: 24273135
Drug: Lenalidomide maintenance
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide maintenance therapy (at last tolerated dose until progression, with or without 50 mg prednisone every other day).
Trial: 24273135
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy (combination of drugs mentioned).
Trial: 24273135
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy (combination of drugs mentioned).
Trial: 24273151
Drug: Ciclopirox olamine
RxNorm normalized name: Ciclopirox Olamine
DrugBank: Ciclopirox (DB01188)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclopirox olamine 10 mg/m² once daily
Trial: 24273151
Drug: Ciclopirox olamine
RxNorm normalized name: Ciclopirox Olamine
DrugBank: Ciclopirox (DB01188)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclopirox olamine 40 mg/m² once daily
Trial: 24273151
Drug: Ciclopirox olamine
RxNorm normalized name: Ciclopirox Olamine
DrugBank: Ciclopirox (DB01188)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclopirox olamine 80 mg/m² four times daily
Trial: 24273151
Drug: Ciclopirox olamine
RxNorm normalized name: Ciclopirox Olamine
DrugBank: Ciclopirox (DB01188)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclopirox olamine (various doses)
Trial: 24273570
Drug: Newer antiepileptic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Newer antiepileptic drugs (AEDs) in monotherapy or combination (24.6% of patients)
Trial: 24273570
Drug: Older antiepileptic
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Older antiepileptic drugs (AEDs) or combination of older and newer AEDs (75.4% of patients)
Trial: 24273570
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment modifications
Trial: 24275632
Drug: Antiarrhythmic drug
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drug use
Trial: 24276047
Drug: EZN-3042 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EZN-3042 2.5 mg/kg/dose administered as a single agent on days -5 and -2, then in combination with a 4-drug reinduction chemotherapy on days 8, 15, 22, and 29.
Trial: 24276047
Drug: EZN-3042 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EZN-3042 2.5 mg/kg/dose (single agent)